Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with... Objective To identify a reliable early indicator of deriving progression-free survival (PFS) benefit in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with octreotide long-acting repeatable (LAR). Methods We investigated the images of 50 patients with well-differentiated advanced GEP-NETs treated with LAR octreotide and underwent baseline and follow-up thoracic, abdominal, and pelvic computed tomography. Receiver-operating characteristic (ROC) analysis and the Kaplan-Meier method were used to identify the optimal threshold to distinguish between those with and without significant improvement of PFS. Results The optimal threshold for determining a response to octreotide LAR was -10% ΔSLD, with a sensitivity and specificity of 85.7% and 80%, respectively. At this threshold, 19 patients were responders and 31 were non-responders; the median PFS was 20.2 and 7.6 months in responders and non-responders (hazard ratio, 2.66; 95% confidence interval, 1.32–5.36). Conclusion A 10% shrinkage in tumor size is an optimal early predictor of response to octreotide LAR in advanced GEP-NETs. Key points � Octreotide LAR can significantly prolong PFS among patients with well-differentiated advanced GEP-NETs. � No optimal tumor size-based response criteria are reported in GEP-NETs with octreotide. � Ten percent tumor shrinkage is a reliable indicator of the response to octreotide for advanced GEP-NETs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Radiology Springer Journals

CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/ct-evaluation-of-response-in-advanced-gastroenteropancreatic-k0dW09NGy2
Publisher
Springer Journals
Copyright
Copyright © 2018 by European Society of Radiology
Subject
Medicine & Public Health; Imaging / Radiology; Diagnostic Radiology; Interventional Radiology; Neuroradiology; Ultrasound; Internal Medicine
ISSN
0938-7994
eISSN
1432-1084
DOI
10.1007/s00330-018-5512-1
Publisher site
See Article on Publisher Site

Abstract

Objective To identify a reliable early indicator of deriving progression-free survival (PFS) benefit in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with octreotide long-acting repeatable (LAR). Methods We investigated the images of 50 patients with well-differentiated advanced GEP-NETs treated with LAR octreotide and underwent baseline and follow-up thoracic, abdominal, and pelvic computed tomography. Receiver-operating characteristic (ROC) analysis and the Kaplan-Meier method were used to identify the optimal threshold to distinguish between those with and without significant improvement of PFS. Results The optimal threshold for determining a response to octreotide LAR was -10% ΔSLD, with a sensitivity and specificity of 85.7% and 80%, respectively. At this threshold, 19 patients were responders and 31 were non-responders; the median PFS was 20.2 and 7.6 months in responders and non-responders (hazard ratio, 2.66; 95% confidence interval, 1.32–5.36). Conclusion A 10% shrinkage in tumor size is an optimal early predictor of response to octreotide LAR in advanced GEP-NETs. Key points � Octreotide LAR can significantly prolong PFS among patients with well-differentiated advanced GEP-NETs. � No optimal tumor size-based response criteria are reported in GEP-NETs with octreotide. � Ten percent tumor shrinkage is a reliable indicator of the response to octreotide for advanced GEP-NETs.

Journal

European Radiology – Springer Journals

Published: Jun 6, 2018

References

  • One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    Yao, JC; Hassan, M; Phan, A
  • Neuroendocrine tumors of the diffuse neuroendocrine system
    Gustafsson, BI; Kidd, M; Modlin, IM
  • Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
    Ramage, JK; Ahmed, A; Ardill, J
  • Neuroendocrine tumors: a critical appraisal of management strategies
    Vinik, AI; Anthony, L; Boudreaux, JP
  • A simplified prognostic system for resected pancreatic neuroendocrine neoplasms
    Ballian, N; Loeffler, AG; Rajamanickam, V; Norstedt, PA; Weber, SM; Cho, CS
  • The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors
    Schimmack, S; Svejda, B; Lawrence, B; Kidd, M; Modlin, IM
  • Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group
    Kocha, W; Maroun, J; Kennecke, H
  • Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view
    Fazio, N; Spada, F; Giovannini, M
  • First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
    Strosberg, JR; Fine, RL; Choi, J
  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
    Raymond, E; Dahan, L; Raoul, JL
  • New targeted agents in gastroenteropancreatic neuroendocrine tumors
    Benavent, M; Miguel, MJ; Garcia-Carbonero, R
  • Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases—a systematic review
    Yang, TX; Chua, TC; Morris, DL
  • Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up
    Akyildiz, HY; Mitchell, J; Milas, M; Siperstein, A; Berber, E
  • Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques
    Atwell, TD; Charboneau, JW; Que, FG
  • Liver transplantation for unresectable neuroendocrine tumor liver metastases
    Rossi, RE; Burroughs, AK; Caplin, ME
  • Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin
    Jann, H; Denecke, T; Koch, M; Pape, UF; Wiedenmann, B; Pavel, M
  • Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients
    Attanasio, R; Mainolfi, A; Grimaldi, F
  • PROMID Study Group. Placebo controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
    Rinke, A; Müller, HH; Schade-Brittinger, C
  • Lanreotide in metastatic enteropancreatic neuroendocrine tumors
    Caplin, ME; Pavel, M; Ruszniewski, P
  • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    Therasse, P; Arbuck, SG; Eisenhauer, EA
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer, EA; Therasse, P; Bogaerts, J
  • Are we ready for the 10% solution?
    Chen, HX; Rubinstein, LV; Shankar, LK; Abrams, JS
  • 10% tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study
    Krajewski, KM; Franchetti, Y; Nishino, M
  • Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
    Thiam, R; Fournier, LS; Trinquart, L
  • Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma
    Krajewski, KM; Guo, M; Abbeele, AD
  • Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study
    Oudard, S; Thiam, R; Fournier, LS
  • Reproducibility of linear tumor measurements using PACS: comparison of caliper method with edge-tracing method
    Monsky, WL; Raptopoulos, V; Keogan, MT
  • Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine
    Krajewski, KM; Fougeray, R; Bellmunt, J
  • Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
    Cremolini, C; Loupakis, F; Antoniotti, C
  • RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Krajewski, KM; Nishino, M; Ramaiya, NH; Choueiri, TK
  • Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response
    Erasmus, JJ; Gladish, GW; Broemeling, L